Regeneron Pharmaceuticals Stock News

Zacks Investment Research cut shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong-buy rating to a hold rating in a research report released on Thursday, Zacks.com reports. Zacks Investment Research currently has $653.00 target price on the biopharmaceutical companys stock. According to Zacks, Regeneron posted better-than-expected third-quarter 2021 results, beating on both earnings and sales. Strong []

Hall Laurie J Trustee lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.7% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 150 shares of the biopharmaceutical companys stock after selling 30 shares during the period. Hall Laurie J Trustees holdings in Regeneron Pharmaceuticals were worth []

Regeneron Pharmaceuticals Inc. REGN, +0.73% said late Friday its board has authorized a share buyback program of up to $3 billion, saying it's an opportunity to continue to invest in the business give

The European Commission (EC) has approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and Ronapreve in the European Union (EU) and othe

Regeneron (REGN) and partner Roche obtain a positive opinion from CHMP for their antibody cocktail for the treatment of non-hospitalized patients with confirmed COVID-19 and to prevent the disease.

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) REGEN-COV. The casiriv

More than a year and a half into the Covid-19 pandemic, the world is changing. More people are returning to the office after months of working at home and restaurants have reopened.

Check out these biotech stocks that could prove to be valuable additions to your portfolio.

REGN vs. TECH: Which Stock Is the Better Value Option?

The Dow is +140 points, the S&P 500 +10 and the Nasdaq +2 points in the pre-market.

Markets Up on COVID Pill News

One dose of the antibody cocktail, given via four injections, cut the risk of contracting Covid-19 by over 80%.

Regeneron CEO Leonard Schleifer joins CNBC's 'Squawk Box' to discuss the latest data around its Covid-19 antibody cocktail, which the company says provides long-term protection against the disease.

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) on Monday said a single dose of REGEN-COV triggers long-term immunity against COVID-19. Shares of the biotech company were up more than 1.0% in premarket t